Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction

Mayo Clinic Proceedings

Volumn 82, Issue 2, 2007, Pages 196-202

  Raveendran, Ganesh ^a,b   Ting, Henry H ^a   Best, Patricia J ^a   Holmes Jr , David R ^a   Lennon, Ryan J ^a   Singh, Mandeep ^a   Bell, Malcolm R ^a   Long, Kirsten Hall ^a   Rihal, Charanjit S ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; DEATH; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROPORTIONAL HAZARDS MODEL; RETROPERITONEAL HEMORRHAGE; ST SEGMENT ELEVATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 33846664474     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.2.196     Document Type: Article

References (20)

1. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in Lancet. 2002;359:2120]. Lancet. 2002;359:189-198.
2. EPIC Investigation. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
3. CAPTURE Study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina [published correction appears in Lancet. 1997;350:744]. Lancet. 1997;349:1429-1435.
4. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
5. EPISTENT Investigators (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting). Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
6. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
7. ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy). Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037-2044.
8. PURSUIT Trial Investigators (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
9. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med. 1998;339:415]. 1998;338:1488-1497.
10. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
11. PARAGON Investigators (Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network). International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 1998;97:2386-2395.
12. Brener SJ, Barr LA, Burchenal JE, et al, ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-741.
13. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
14. Montalescot G, Barragan P, Wittenberg O, et al, ADMIRAL Investigators (Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up). Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
15. Stone GW, Grines CL, Cox DA, et al, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
16. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-1885.
17. Kandzari DE, Hasselblad V, Tcheng JE, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004;147:457-462.
18. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-1889.
19. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293:1759-1765.
20. Kaul U, Gupta RK, Haridas KK, et al, Integrilin in Acute Myocardial Infarction (INAMI) Stenting Study Investigators. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study [published correction appears in Catheter Cardiovasc Interv. 2003;59:419]. Catheter Cardiovasc Interv. 2002;57:497-503.